Improvement coming but there's much more to go

In the US, more than 6 million Americans are living with Alzheimer's disease and by 2060, Alzheimer's disease cases are predicted to rise to an estimated 14 million people. However, a number of therapeutics are entering the marketplace this year showing promise of reducing plaque in the brain and a slowing of cognitive decline. Data so far suggests relatively modest improvement but Geoff believes a combination of some of these therapies and greater innovation in diagnostics can lead to greater improvements over the next 5-10 years. Charlie predicts there will be multiple players in the Alzheimer therapeutic space and with pricing trending downward, the cost benefits may lead to a multi-billion dollar market.

 

You may also enjoy listening to the Merrill Perspectives podcast, featuring conversations on the big stories, news and trends affecting your everyday financial life.

 

"Bank of America" and “BofA Securities” are the marketing names for the global banking businesses and global markets businesses (which includes BofA Global Research) of Bank of America Corporation. Lending, derivatives, and other commercial banking activities are performed globally by banking affiliates of Bank of America Corporation, including Bank of America, N.A., Member FDIC. Securities, trading, research, strategic advisory, and other investment banking and markets activities are performed globally by affiliates of Bank of America Corporation, including, in the United States, BofA Securities, Inc. a registered broker-dealer and Member of FINRA and SIPC, and, in other jurisdictions, by locally registered entities.

©2023 Bank of America Corporation. All rights reserved.